Aastrom Biosciences reports positive interim results for two trials
Regenerative medicine company Aastrom Biosciences, Inc. (Nasdaq: ASTM) today announced positive interim results from two separate research groups using autologous stem cell products manufactured with the company’s Tissue Repair Cell Technology platform.
Aastrom said the first study yielded positive results after Aastrom’s Vascular Repair Cells were used for the treatment of chronic diabetic foot wounds associated with critical limb ischemia. Additionally, in a separate study, Aastrom found using Bone Repair Cells to treat osteonecrosis of the femoral head also yielded positive results.
Shares of Aastrom (ASTM) gained $0.08, or 5.84%, to $1.45 in pre-market trading. Over the last 52 weeks, shares have ranged from $1.08 to $1.67.
